<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24320792</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2180</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2013</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>BMC microbiology</Title><ISOAbbreviation>BMC Microbiol</ISOAbbreviation></Journal><ArticleTitle>Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses.</ArticleTitle><Pagination><StartPage>287</StartPage><MedlinePgn>287</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2180-13-287</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus 71 (EV71) is major cause of hand, foot and mouth disease. Large epidemics of EV71 infection have been recently reported in the Asian-Pacific region. Currently, no vaccine is available to prevent EV71 infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The peptide (VP4N20) consisting of the first 20 amino acids at the N-terminal of VP4 of EV71 genotype C4 were fused to hepatitis B core (HBcAg) protein. Expression of fusion proteins in E. coli resulted in the formation of chimeric virus-like particles (VLPs). Mice immunized with the chimeric VLPs elicited anti-VP4N20 antibody response. In vitro microneutralization experiments showed that anti-chimeric VLPs sera were able to neutralize not only EV71 of genotype C4 but also EV71 of genotype A. Neonatal mice model confirmed the neutralizing ability of anti-chimeric VLPs sera. Eiptope mapping led to the identification of a "core sequence" responsible for antibody recognition within the peptide.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Immunization of chimeric VLPs is able to elicit antibodies displaying a broad neutralizing activity against different genotypes of EV71 in vitro. The "core sequence" of EV71-VP4 is highly conserved across EV71 genotypes. The chimeric VLPs have a great potential to be a novel vaccine candidate with a broad cross-protection against different EV71 genotypes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Miao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Xiangqian</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuming</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Cen</LastName><ForeName>Shan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Paul K S</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Life Science and Bioengineering, Beijing University of Technology, 100, Pingleyuan, Chaoyang District, Beijing 100124, PR China. sunxinbh@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Wang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Microbiol</MedlineTA><NlmUniqueID>100966981</NlmUniqueID><ISSNLinking>1471-2180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006512">Hepatitis B Core Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056738" MajorTopicYN="Y">Cross Protection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006512" MajorTopicYN="N">Hepatitis B Core Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24320792</ArticleId><ArticleId IdType="pmc">PMC4029445</ArticleId><ArticleId IdType="doi">10.1186/1471-2180-13-287</ArticleId><ArticleId IdType="pii">1471-2180-13-287</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An Apparently New Enterovirus Isolated from Patients with Disease of the Central Nervous System. J Infect Dis. 1974;13(3):304&#x2013;309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 1995;13(2&#x2013;3):195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y-C, Ho M-S, Wu J-C, Chen W-J, Huang J-H, Chou S-T, Hu Y-C. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;13(15):1855&#x2013;1862. doi: 10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuthill T, Groppelli E, Hogle J, Rowlands D. In: Cell Entry by Non-Enveloped Viruses. 343. Johnson JE, editor. Germany: Springer Berlin Heidelberg; 2010. Picornaviruses; pp. 43&#x2013;89.</Citation></Reference><Reference><Citation>Chow M, Newman JFE, Filman D, Hogle JM, Rowlands DJ, Brown F. Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature. 1987;13(6122):482&#x2013;486. doi: 10.1038/327482a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/327482a0</ArticleId><ArticleId IdType="pubmed">3035380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis JK, Bothner B, Smith TJ, Siuzdak G. Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci. 1998;13(12):6774&#x2013;6778. doi: 10.1073/pnas.95.12.6774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.12.6774</ArticleId><ArticleId IdType="pmc">PMC22631</ArticleId><ArticleId IdType="pubmed">9618488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C. et al.A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;13(4):424&#x2013;429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;13(1):91&#x2013;107. doi: 10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y, Taya K, Nakashima K, Ohyama T, Kobayashi JM, Ohkusa Y, Okabe N. Risk factors for severe hand foot and mouth disease. Pediatr Int. 2010;13(2):203&#x2013;207. doi: 10.1111/j.1442-200X.2009.02937.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-200X.2009.02937.x</ArticleId><ArticleId IdType="pubmed">19663940</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan D, van der Sanden S, Zeng H, Li W, Zheng H, Ma C, Su J, Liu Z, Guo X, Zhang X. et al.Population Dynamics and Genetic Diversity of C4 Strains of Human Enterovirus 71 in Mainland China, 1998&#x2013;2010. PLoS ONE. 2012;13(9):e44386. doi: 10.1371/journal.pone.0044386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044386</ArticleId><ArticleId IdType="pmc">PMC3440427</ArticleId><ArticleId IdType="pubmed">22984501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, Chow VTK. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: The role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;13(12):e1076&#x2013;e1081. doi: 10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai M, Masaki A, Hasegawa S, Obara M, Horimoto E, Nakamura K, Tanaka Y, Endo K, Tanaka K, Ueda J. et al.Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Japanese journal of infectious diseases. 2009;13(4):254&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">19628900</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S-C, Chang H-L, Yan T-R, Cheng Y-T, Chen K-T. An Eight-Year Study of Epidemiologic Features of Enterovirus 71 Infection In Taiwan. AmJTrop Med Hyg. 2007;13(1):188&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620652</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K-T, Chang H-L, Wang S-T, Cheng Y-T, Yang J-Y. Epidemiologic Features of Hand-Foot-Mouth Disease and Herpangina Caused by Enterovirus 71 in Taiwan, 1998&#x2013;2005. Pediatrics. 2007;13(2):e244&#x2013;e252. doi: 10.1542/peds.2006-3331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-3331</ArticleId><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;13(11):778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Chou A-H, Lien S-P, Lin H-Y, Liu S-J, Chang J-Y, Guo M-S, Chow Y-H, Yang W-S, Chang KH-W. et al.Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;13(26):4362&#x2013;4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang GH, Luo YJ, Wu XY, Si BY, Lin L, Zhu QY. Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virology journal. 2010;13:106. doi: 10.1186/1743-422X-7-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-106</ArticleId><ArticleId IdType="pmc">PMC2887433</ArticleId><ArticleId IdType="pubmed">20500892</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;13(1):61&#x2013;68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes and infection/Institut Pasteur. 2007;13(11):1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, Hao Y, Ma CM, Li WB, Lin SZ, Gao XZ, Liu XL, Xu YF. et al.Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;13(46):7444&#x2013;7451. doi: 10.1016/j.vaccine.2010.08.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.080</ArticleId><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoke-Fun C, AbuBakar S. Phylogenetic evidence for inter-typic recombination in the emergence of human enterovirus 71 subgenotypes. BMC microbiology. 2006;13:74. doi: 10.1186/1471-2180-6-74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-6-74</ArticleId><ArticleId IdType="pmc">PMC1569848</ArticleId><ArticleId IdType="pubmed">16939656</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Kiang D, Smith DJ, Wang JR. Evolution of re-emergent virus and its impact on enterovirus 71 epidemics. Experimental biology and medicine (Maywood, NJ) 2011;13(8):899&#x2013;908. doi: 10.1258/ebm.2010.010233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/ebm.2010.010233</ArticleId><ArticleId IdType="pubmed">21715436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. The New England journal of medicine. 1999;13(13):929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A. et al.An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virology journal. 2010;13:94. doi: 10.1186/1743-422X-7-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan X, Cui A, Mao N, Xu S, Zhu Z, Zhou J, Shi J, Zhao Y, Wang X. et al.Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14&#xa0;years. PLoS One. 2013;13(2):e56341. doi: 10.1371/journal.pone.0056341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056341</ArticleId><ArticleId IdType="pmc">PMC3575343</ArticleId><ArticleId IdType="pubmed">23441179</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;13(5&#x2013;6):895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, Lin YL, Chiang BL, Chen WJ, Hu YC. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine. 2010;13(43):6951&#x2013;6957. doi: 10.1016/j.vaccine.2010.08.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.052</ArticleId><ArticleId IdType="pubmed">20797455</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genetic vaccines and therapy. 2007;13:6. doi: 10.1186/1479-0556-5-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu CH, Chu C, He CC, Lin TY. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes and infection/Institut Pasteur. 2006;13(7):1671&#x2013;1678. doi: 10.1016/j.micinf.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2006.01.021</ArticleId><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. Journal of virology. 2007;13(17):9386&#x2013;9395. doi: 10.1128/JVI.02856-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02856-06</ArticleId><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Wang J, Liu L, Zhao H, Shi H, Zhang Y, Jiang L, Li Q. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Human vaccines. 2010;13(12):1028&#x2013;1037. doi: 10.4161/hv.6.12.12982.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.6.12.12982</ArticleId><ArticleId IdType="pubmed">21150270</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T. et al.Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One. 2013;13(1):e54451. doi: 10.1371/journal.pone.0054451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0054451</ArticleId><ArticleId IdType="pmc">PMC3553120</ArticleId><ArticleId IdType="pubmed">23372725</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, Na R, Liang Y, Wang L, Li Q. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine. 2011;13(37):6269&#x2013;6275. doi: 10.1016/j.vaccine.2011.06.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.06.044</ArticleId><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, Cai F, Gao Z, McMinn PC. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine. 2011;13(29&#x2013;30):4829&#x2013;4838.</Citation><ArticleIdList><ArticleId IdType="pubmed">21550375</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. Journal of virology. 1999;13(12):9969&#x2013;9975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113047</ArticleId><ArticleId IdType="pubmed">10559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Roivainen M, Piirainen L, Ry&#xe4; T, N&#xe4;rv&#xe4;nen A, Hovi T. An Immunodominant N-Terminal Region of VP1 Protein of Poliovirion That Is Buried in Crystal Structure Can Be Exposed in Solution. Virology. 1993;13(2):762&#x2013;765. doi: 10.1006/viro.1993.1427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1993.1427</ArticleId><ArticleId IdType="pubmed">8393243</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Yafal AG, Lee YM, Hogle J, Chow M. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature. J Virol. 1994;13(6):3965&#x2013;3970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236902</ArticleId><ArticleId IdType="pubmed">7514682</ArticleId></ArticleIdList></Reference><Reference><Citation>Katpally U, Fu TM, Freed DC, Casimiro DR, Smith TJ. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. Journal of virology. 2009;13(14):7040&#x2013;7048. doi: 10.1128/JVI.00557-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00557-09</ArticleId><ArticleId IdType="pmc">PMC2704786</ArticleId><ArticleId IdType="pubmed">19403680</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogle J, Chow M, Filman D. Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985;13(4720):1358&#x2013;1365. doi: 10.1126/science.2994218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2994218</ArticleId><ArticleId IdType="pubmed">2994218</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricks CE, Hogle JM. Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J Virol. 1990;13(5):1934&#x2013;1945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC249347</ArticleId><ArticleId IdType="pubmed">2157861</ArticleId></ArticleIdList></Reference><Reference><Citation>Greve JM, Forte CP, Marlor CW, Meyer AM, Hoover-Litty H, Wunderlich D, McClelland A. Mechanisms of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1. J Virol. 1991;13(11):6015&#x2013;6023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250267</ArticleId><ArticleId IdType="pubmed">1681115</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis MP, Bottley G, Beales LP, Killington RA, Rowlands DJ, Tuthill TJ. Recombinant VP4 of human rhinovirus induces permeability in model membranes. Journal of virology. 2008;13(8):4169&#x2013;4174. doi: 10.1128/JVI.01070-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01070-07</ArticleId><ArticleId IdType="pmc">PMC2293005</ArticleId><ArticleId IdType="pubmed">18256154</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>